Stamford Health
Stamford Health

Short TeRm Intensified Pembrolizumab (Keytruda) and Tivozanib

Back to Results

Short TeRm Intensified Pembrolizumab (Keytruda) and Tivozanib

Alliance A032201 – Short TeRm Intensified Pembrolizumab (Keytruda) and Tivozanib for High-risk Renal Cell Carcinoma (STRIKE) (NCT06661720)

Principal Investigator(s)

Anthony Gulati, MD

Location

Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.

ACCEPT AND CLOSE